Britain-based AstraZeneca will acquire the U.S. fish oil drug-maker Omthera Pharmaceuticals in a transaction valued at up to $443 million. The purchase is seen as an effort by AstraZeneca to round out its cardiovascular offerings and compete with GlaxoSmithKline and others that already sell fish-oil pharmaceuticals. Omthera's Epanova, a mixture of fish-oil-derived fatty acids, should be submitted for U.S. regulatory approval mid-year, according to this article.

Full Story:

Related Summaries